Galapagos Genomics said that Andrea Grant, its director of business development, has been named the managing director of the company’s new discovery and validation business unit Galadeno.
Grant joined Galapagos in 2003 from the healthcare practice Cambridge Consultants, where she was a senior consultant. Prior to this, she was commercial director at Incyte Genomics. According to Galapagos, she has also works as a senior scientist at Glaxo Wellcome, and holds a PhD in molecular medicine from Cambridge University.
Also joining Galadeno is Galapagos co-founder Helmuth van Es, who will be the new unit’s chief scientific officer. Van Es previously was a group leader at IntroGene, which is now Crucell, and holds a PhD from the University of Amsterdam, according to Galapagos.